Emergent BioSolutions has signed a $174 million deal with AstraZeneca to develop and manufacture Astra’s COVID-19 vaccine candidate. Emergent will produce 300 million doses of its potential COVID-19 vaccine pledged to the US. Astra has committed 2 billion doses of the vaccine. The vaccine has been co-developed by Oxford University and is among the first to move into mid-stage trials.